Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 50.19

+1.8%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: zeta1961	3/29/2007 12:29:17 PM
	Read Replies (2) of 52153

DNDN AC meeting..I tuned in when FDA statisticians were giving presentations..although they pointed out the technical stat issues..they had no conviction that they should prevent approval..opposite, I thought..they mentioned OS being gold standard regardless that it wasn't an initial endpoint, that their sensitivity tests did NOT indicate a false good bias in the OS in 9901 which did show stat sig for OS..one of the panel members brought up it's now known that TTP and PFS are not good indicators of OS in prostate cancer and the FDA rep reminded that this study was planned in 1998.. Edit: This meeting is in stark contrast to ODAC 04 with GNTA/ALTH..no acrimony, I'd buy some shares if it wasn't halted..adcocates are speaking now..

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next